Increased serum levels of interleukin (IL)-5, IL-6 and IL-8 in bullous pemphigoid

Journal of Dermatological Science

Volumn 16, Issue 2, 1998, Pages 152-157

  Inaoki, M ^a   Takehara, K ^a  

^a KANAZAWA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

Bullous pemphigoid; IL 5; IL 6; IL 8

Indexed keywords

CD23 ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; HUMAN; IMMUNOPATHOLOGY; MALE; PEMPHIGOID; PRIORITY JOURNAL;

EID: 0030635274     PISSN: 09231811     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0923-1811(97)00044-3     Document Type: Article

References (37)

1. [1] Giudice GJ, Emery DJ, Diaz LA. Cloning and primary structural analysis of the bullous pemphigoid autoantigen BP180. J Invest Dermatol 1992;99:243-50.
2. [2] Sawamura D, Li K, Chu M-L, Uitto J. Human bullous pemphigoid antigen (BPAG1): amino acid sequences deduced from cloned cDNAs predict biologically important peptide segments and protein domains. J Biol Chem 1991;266:17784-90.
3. [3] Grando SA, Glukhenky BT, Drannik GN, Epshtein EV, Kostromin AP, Korostash TA. Mediators of inflammation in blister fluids from patients with pemphigus vulgaris and bullous pemphigoid. Arch Dermatol 1989;125:925-30.
4. [4] Zillikens D, Ambach A, Schuessler M, Dummer R, Hartmann AA, Burg G. The interleukin-2 receptor in lesions and serum of bullous pemphigoid. Arch Dermatol Res 1992;284:141-5.
5. [5] Kaneko F, Minagawa T, Takiguchi Y, Suzuki M, Itoh N. Role of cell-mediated immune reaction in blister formation of bullous pemphigoid. Dermatology 1992;184:34-9.
6. [6] Schaller J, Giese T, Ladusch M, Haustein UF. Interleukin-2 receptor expression and interleukin-2 production in bullous pemphigoid. Arch Dermatol Res 1990;282:223-6.
7. [7] Ahmed AR, Hijri K, Arab-Kermani V. Interleukin-2 production ln bullous pemphlgold. Arch Dermatol Res 1984;276:330-2.
8. [8] Zillikens D, Schuessler M, Dummer R, Porzsolt F, Hartmann AA, Burg G. Tumour necrosis factor in blister fluids of bullous pemphigoid. Eur J Dermatol 1992;2:429-31.
9. [9] Takematsu H, Ohta H, Tagami H. Determination of tumor necrosis factor in blister fluids of bullous pemphigoid. Arch Dermatol Res 1991;283:131-2.
10. [10] Zentner A, Rendl J, Grelle I, Dummer R, Brocker EB, Zillikens D. Elevated levels of soluble tumour necrosis factor receptor I in blister fluids of bullous pemphigoid and suction blisters. Arch Dermatol Res 1994;286:355-7.
11. [11] Endo H, Iwamoto I, Fujita M, Okamoto S, Yoshida S. Increased immunoreactive interleukin-5 levels in blister fluids of bullous pemphigoid. Arch Dermatol Res 1992;284:312-4.
12. [12] Tamaki K, So K, Furoya T, Furue M. Cytokine profile of patients with bullous pemphigoid. Br J Dermatol 1994;130:128-9.
13. [13] Schmidt E, Ambach A, Bastian B, Broker E, Zillikens D. Elevated levels of interleukin-8 in blister fluid of bullous pemphigoid compared with suction blisters of healthy control subjects. J Am Acad Dermatol 1996;34:310-2.
14. [14] Furukawa F, Kumagai S, Sakamoto Y, Takigawa M, Imamura S. Elevated serum levels of IgE-binding factor/soluble CD23 in bullous pemphigoid. J Dermatol Sci 1994;7:150-4.
15. [15] Maekawa N, Hosokawa H, Soh H, Kasahara M, Izumi H, Yodoi J, Asada Y. Serum levels of soluble CD23 in patients, with bullous pemphigoid. J Dermatol 1995;22:310-5.
16. [16] Sugita Y, Nagatani T, Ikazawa Z, Nomura K, Watanabe Y, Uitto J, Nakajima H. Modulation of bullous pemphigoid antigen gene expression by γ-interferon in cultured keratinocytes. Br J Dermatol 1992;126:468-73.
17. [17] Sollberg S, Ryynanen J, Olsen DR, Uitto J. Transforming growth factor-β up-regulates the expression of the genes for β 4 integrin and bullous pemphigoid antigens (BPAG1 and BPAG2) in normal and transformed human keratinocytes. J Invest Dermatol 1992;99:409-14.
18. [18] Zurawski G, de Vries JE. Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells. Immunol Today 1994;15:19-26.
19. [19] Lever WF. Pemphigus and pemphigoid: a review of the advances made since 1964. J Am Acad Dermatol 1979;1:231.
20. [20] McKenzie ANJ, Sanderson CJ. Interleukin-5. Chem Immunol 1992;51:135-52.
21. [21] Hirano T. The biology of interleukin-6. Chem Immunol 1992;51:153-80.
22. [22] Matsushima K, Baldwin ET, Mukaida N. Interleukin-8 and MCAF: novel leukocyte recruitment and activating cytokines. Chem Immunol 1992;51:236-65.
23. [23] Kuhns DB, DeCarlo E, Hawk DM, Gallin JI. Dynamics of the cellular and humoral components of the inflammatory response elicited in skin blisters in humans. J Clin Invest 1992;89:1734-40.
24. [24] Kagi MK, Wuthrich B, Montano E, Barandum J, Blaser K, Walker C. Differential cytokine profiles in peripheral blood lymphocyte supernatants and skin biopsies from patients with different forms of atopic dermatitis, psoriasis and normal individuals. Int Arch Allergy Immunol 1994;103:332-40.
25. [25] Drabick JJ, Magill AJ, Smith XJ, Nutman TB, Benson PM. Hypereosinophilic syndrome associated with HIV infection. Military Medical Consortium for applied retroviral research. South Med J 1994;87:525-9.
26. [26] Yoshizaki K, Kuritani T, Kishimoto T. Interleukin-6 in autoimmune disorders. Seminars Immunol 1992;4:155-66.
27. [27] Bonifati C, Carducci M, Cordiali Fei P, Trento E, Sacerdoti G, Fazio M, Ameglio F. Correlated increases of tumor necrosis factor-α, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients - relationships with disease severity. Clin Exp Dermatol 1994;19:383-7.
28. [28] Nakamura T, Oishi M, Johno M, Ono T, Honda M. Serum levels of interleukin 6 in patients with pustulosis palmaris et plantaris. J Dermatol 1993;20:763-6.
29. [29] Kodama A, Tani M, Hori K, Tozuka T, Matsui T, Ito M, Nakao S, Fujita T, Kobayashi H. Systemic and cutaneous plasmacytosis with multiple skin lesions and polyclonal hypergammaglobulinemia: significant serum interleukin-6 levels. Br J Dermatol 1992;127:49-53.
30. [30] Toshitani A, Ansel JC, Chan SC, Li S, Hanifin JM. Increased interleukin 6 production by T cells derived from patients with atopic dermatitis. J Invest Dermatol 1993;100:299-304.
31. [31] Gammon WR, Merritt CC, Levis DM, Sams WM Jr., Carlo JR. An in vitro model of immune complex mediated basement membrane zone separation caused by antibodies, leukocytes, and complement. J Invest Dermatol 1982;78:285-90.
32. [32] Iwatsuki K, Tagami H, Yamada M. Induction of leukocyte and adherence at the basement membrane zone with subsequent activation of their metabolic pathway by pemphigoid antibodies: in vitro studies. J Invest Dermatol 1982;78:285-90.
33. [33] Larsen CG, Anderson AO, Appella E, Oppenheim JJ, Matsushima K. Neutrophil activating protein (NAP-1) is also chemotactic for T lymphocytes. Science 1989;243:1464-6.
34. [34] Kimata H, Lindley I. Detection of plasma interleukin-8 in atopic dermatitis. Arch Dis Child 1994;70:119-22.
35. [35] Nickoloff BJ, Karabin GD, Barker JNW, Grifith CEM, Sarma V, Mitra RS, Elder JT, Kunkel SL, Dixit VM. Cellular localization of IL-8 and its inducer, tumor necrosis factor-alpha, in psoriasis. Am J Pathol 1991;138:129-40.
36. [36] Lemster BH, Carroll RB, Rilo HR, Johnson N, Nikaoin A, Thomson AW. IL-8/IL-8 receptor expression in psoriasis and the response to systemic tacrolimus (FK 506) therapy. Clin Exp Immunol 1995;99:148-54.
37. [37] Teranishi Y, Mizutani H, Murata M, Shimizu M, Matsushima K. Increased spontaneous production of IL-8 in peripheral blood monocytes from the psoriatic patient: relation to focal infection and response to tratments. J Dermatol Sci 1995;10:8-15.